VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $7.14 Million Investment in Boston Scientific Corporation $BSX

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, HoldingsChannel reports. The institutional investor bought 66,500 shares of the medical equipment provider’s stock, valued at approximately $7,143,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. 1248 Management LLC bought a new stake in Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific during the first quarter worth about $27,000. Sound Income Strategies LLC boosted its position in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new position in Boston Scientific during the second quarter valued at approximately $37,000. Finally, Activest Wealth Management boosted its position in Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 373 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Leerink Partners upped their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. BTIG Research raised their target price on Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their target price for the company from $118.00 to $125.00 in a report on Monday, September 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $120.71.

Boston Scientific Stock Performance

BSX stock opened at $100.56 on Tuesday. The stock has a 50-day moving average price of $101.25 and a 200-day moving average price of $101.85. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a market cap of $149.01 billion, a PE ratio of 59.86, a price-to-earnings-growth ratio of 2.39 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the company posted $0.62 EPS. The business’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.